Nuvectis Pharma Inc expected to post a loss of 26 cents a share - Earnings Preview

Nuvectis Pharma

05/08/2024 15:05

* Nuvectis Pharma Inc  NVCT.OQ   NVCT.O  is expected to show
no
change in quarterly revenue when it reports  results on August 7
(estimated) for the period ending June 30 2024
    * 
    * ​LSEG's mean analyst estimate for Nuvectis Pharma Inc is
for a
loss of 26 cents per share. 
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 3 "strong buy" or "buy," no
"hold" and no "sell" or "strong sell."  
    * The mean earnings estimate of analysts was unchanged in
the last
three months. ​
    * Wall Street's median 12-month price target for Nuvectis
Pharma
Inc is $21.00​, above​ its last closing price of $6.17. ​​​

Previous quarterly performance (using preferred earnings measure
in US dollars). ​
 QUARTER       STARMINESM  LSEG IBES  ACTUAL    BEAT,   SURPRI
 ENDING        ARTESTIMAT  ESTIMATE             MET,    SE %
               E®                               MISSED  
 Mar. 31 2024  -0.40       -0.40      -0.25     Beat    37
 Dec. 31 2024  -0.36       -0.36      -0.41     Missed  -12.3
 Sep. 30 2023  -0.35       -0.34      -0.37     Missed  -8.1​
 Jun. 30 2023  -0.29       -0.29      -0.38     Missed  -30.3
 ​​Mar.        -0.44       -0.44      -0.27     Beat    38.8
 31 2023                                                
 Dec. 31 2022              -0.38                        ​
 Sep. 30 2022  -0.27       -0.27      -0.42     Missed  -55.6
 Jun. 30 2022  -0.22       -0.23      -0.28     Missed  -20
 This summary was machine generated August 5 at 14:05 GMT.  All
figures in US dollars unless otherwise stated. (For questions
concerning the data in this report, contact
Estimates.Support@lseg.com. For any other questions or feedback,
contact RefinitivNewsSupport@thomsonreuters.com)